Galectin Therapeutics Inc. (NASDAQ: GALT) revealed the top-line results of its NAVIGATE clinical trial in a recent press release. The trial evaluated belapectin in patients with cirrhotic portal ...

Galectin Therapeutics Inc. Common Stock (GALT) stock saw a decline, ending the day at $1.04 which represents a decrease of $-0.96 or -48.00% from the prior close of $2. The stock opened at $1.18 and ...

Galectin Therapeutics shares fell after it said the endpoint of a liver-disease treatment trial didn't meet statistical significance. The stock lost more than half its value, falling to about 91 cents ...

Shares of Personalis, Inc. PSNL got a boost, surging 25% to $6.55 after the company and Moderna recently announced a ...

Galectin Therapeutics’ stock has halved since the company revealed its investigational drug failed to significantly reduce ...

Galectin’s shares tanked in premarket trading Friday after the biotech revealed its lead asset missed the primary endpoint ...

Galectin Therapeutics (GALT) reported results from NAVIGATE clinical trial evaluating belapectin in patients with Metabolic ...

Galectin Therapeutics' NAVIGATE trial shows belapectin reduces varices in MASH cirrhosis, but falls short of statistical targets; full data due in early 2025.

Galectin Therapeutics (GALT) announced results from its global clinical trial NAVIGATE evaluating belapectin in patients with Metabolic ...

Galectin Therapeutics (GALT) stock drops 25% as NAVIGATE trial for belapectin in liver disorder MASH fails to meet main goal.

Galectin Therapeutics Inc. (NASDAQ:GALT – Get Free Report) was the recipient of unusually large options trading activity on Monday. Stock investors bought 14,331 put options on the stock. This ...

Selvigaltin is a small molecule commercialized by Galecto, with a leading Phase II program in Decompensated Cirrhosis.